CJC-1295 vs Tesamorelin
Compare the research profiles of CJC-1295 and Tesamorelin. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesCJC-1295
CJC-1295 (with or without DAC)
Category
growth-hormone
Research Level
Phase 2 Clinical Trials
FDA Status
not-approved
Tesamorelin
Tesamorelin (Egrifta)
Category
growth-hormone
Research Level
Phase 4 (Post-Market)
FDA Status
approved
Detailed Comparison
| Aspect | CJC-1295 | Tesamorelin |
|---|---|---|
| Overview | A growth hormone releasing hormone (GHRH) analog that stimulates GH release. Available with DAC (Drug Affinity Complex) for extended half-life or without for shorter action.... | An FDA-approved GHRH analog originally for HIV-associated lipodystrophy. Increasingly used off-label for abdominal fat reduction and muscle growth. One of the few FDA-approved GH-related peptides.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Mimics GHRH to stimulate the pituitary gland to produce and release growth hormone. The DAC version binds to albumin for prolonged effect.... | Stimulates the pituitary gland to produce and release growth hormone naturally. Unlike synthetic HGH, it works through the body's own regulatory mecha... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.